Abstract library

341 results for "glucagon tolerance test".
#1074 Usefulness of a Combination of a 48-Hour Fasting and a Glucagon Tolerance Test
Introduction: The 72-hour fasting test is the gold standard for the diagnosis of insulinoma. However, the test can become a burden for both patients and medical staff and, shortening the duration of fast has been attempted. There are several reports on the high sensitivity of fasting test but only a few reports on its specificity. An insulinoma can be localized using invasive tests such as endoscopic ultrasonography and selective arterial secretagogue injection test. Therefore, insulinoma detection with high specificity may be needed to avoid unnecessary examinations.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Keijiro Ueda
Authors: Ueda K, Lee L, Hijioka M, Igarashi H, ...
#1063 Hypoglycaemia in a Patient with Glucagonoma-Coincidence of a Glucagonoma and Insulinoma in a Patient with Multiple Endocrine Neoplasia Type I
Introduction: We report the case of a 54 year old female with a known MEN1 syndrome with primary Hyperparathyroidism, a Prolactinoma and a pancreatic tumor. The patient complains about episodes of fatigue and sweating, both symptoms improve immediately after a meal.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Vinzenz Stepan
Authors: Ploner F, Plank J, Humer-Fuchs U, Lax S, ...
Keywords: MEN1, Glucagonoma
#691 Pancreatic Focal Alpha Cell Hyperplasia with Hyperglucagonaemia without the Glucagonoma Syndrome
Introduction: Pancreatic alpha cell hyperplasia and hyperglucagonaemia without the glucagonoma syndrome is a rare clinical syndrome not widely recognised. Here we describe a novel mutation in the glucagon receptor gene (GCGR) in a patient with the disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: Helen Miller
Authors: Miller H, Baird D, Kidd M, Cohen P, ...
#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Mark Kidd
Authors: Bodei L, Kidd M, Severi S, Drozdov I, ...
Keywords: NETest, PRRT
#1108 Regression of Paraneoplastic Optic Neuropathy Associated with Glucagonoma After Surgical Resection
Introduction: Glucagonomas-associated ocular manifestations have been exceptionally reported.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Lucie Defour
#2114 Significance of Biochemical Testing in Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare tumors that are frequently diagnosed late in the course of the disease. Several biomarkers have been proposed in the literature for diagnosis in patients with these tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Doctor Azka Athar
Authors: Athar A, ...
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#1497 Circulating Neuroendocrine Tumor Gene Signature, the NETest, Defines Therapy in GEP-NETs
Introduction: Early and precise delineation of therapeutic responses are key issues in GEP-NET management. Imaging has limitations in sensitivity while secretory biomarkers e.g., CgA is controversial.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: NETest, CgA, PCR
#2282 Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Based on Clinical Follow-up and Results of NETest
Introduction: Neuroendocrine neoplasms of the appendix (ANEN) are one of the most commonly identified gastroentropancreatic tumours (GEP). The aim of this retrospective study was to review the value of Somatostatin Receptor Scintigraphy (SRS) in staging and imaging follow-up of patients with confirmed ANEN, NENG1 and NENG2 in single institution.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Sonia Konsek
#113 Prolonged cell survival in xenografts from human digestive endocrine tumors
Introduction: Gastroenteropancreatic endocrine tumors have the capacity to achieve very large tumor masses despite usually very low proliferative rates. This suggests that neoplastic endocrine cells may have long life spans, implying the development of specific mechanisms able to promote cell survival.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Colette Roche